Metabolomic Insights into Chronic Kidney Disease Management

Chronic kidney disease (CKD) affects nearly 10% of the global population and is characterised by progressive loss of renal function, tubular interstitial fibrosis and metabolic dysregulation. Metabolomic analysis – the comprehensive profiling of small-molecule metabolites – has emerged as a powerful tool to uncover novel biomarkers for early detection, stratify patients and illuminate underlying mechanisms. Both untargeted and targeted approaches have revealed disruptions in amino acid, lipid and tryptophan-derived pathways, linking metabolic signatures to inflammatory, oxidative stress and fibrotic processes. When integrated with genomic and microbiome data, these insights highlight complex host–microbe interactions and signalling networks such as NF-κB and Nrf2, suggesting avenues for personalised management. Taken together, metabolomics offers a global lens to monitor disease progression, predict therapeutic responses and develop metabolite-based interventions aimed at slowing or reversing CKD progression.

Research from Nature Portfolio

Seminal untargeted metabolomic work has pinpointed 5-methoxytryptophan (5-MTP) as a metabolite whose serum concentration declines with CKD progression. In experimental models, 5-MTP supplementation mitigates interstitial fibrosis and renal inflammation by suppressing NF-κB activation and bolstering Nrf2-driven antioxidant responses. Genetic modulation of tryptophan hydroxylase-1, the key enzyme in 5-MTP biosynthesis, corroborates its dual role as both biomarker and therapeutic target.

In toxin-induced nephropathy studies, combined lipidomic and metabolomic analyses have revealed that alterations in glycerophospholipid and acyl-carnitine species emerge well before overt histological damage. These early metabolic shifts align with activation of TGF-β and oxidative pathways, offering a window for presymptomatic detection and targeted metabolic interventions.

Metabolomic Insights into Chronic Kidney Disease Management publication trend

The graph below shows the total number of articles in metabolomic insights into chronic kidney disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: Comprehensive analysis of small-molecule metabolites within a biological system.

Biomarker: A measurable indicator of a biological state or condition.

Fibrosis: Pathological accumulation of fibrous connective tissue in an organ.

NF-κB signalling: A pro-inflammatory transcription factor pathway that drives cytokine release.

Nrf2 signalling: An antioxidant response pathway regulating cellular defence mechanisms.

Aryl hydrocarbon receptor (AHR): A ligand-activated transcription factor involved in detoxification and immune responses.

References

1. Targeting Lactobacillus johnsonii to reverse chronic kidney disease. Signal Transduction and Targeted Therapy (2024).
2. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nature Communications (2019).
3. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Scientific Reports (2015).
4. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Scientific Reports (2015).
5. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Frontiers in Pharmacology (2022).